# A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)

> **NCT05984238** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 32 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DEVICE:** ReCET
- **DRUG:** Semaglutide, 1.0 mg/mL
- **OTHER:** Sham procedure

## Key facts

- **NCT ID:** NCT05984238
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-03
- **Primary completion:** 2025-03-21
- **Final completion:** 2026-07
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984238, "A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05984238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*